Abstract
Ranibizumab (Lucentis®) is a Fab-Antibody with high affinity for VEGF, and is being designed to bind to all VEGF isoforms. This quality makes it a powerful drug for VEGF inhibition. Diseases of retinal and choroidal blood vessels are the most prevalent causes of moderate and severe vision loss in developed countries. Vascular endothelial growth factor plays a critical role in the pathogenesis of many of these diseases. Results of the pilot studies showed that intraocular injections of ranibizumab (Lucentis®) decrease the mean retinal thickness and improve the BCVA in all the subjects. Proliferative diabetic retinopathy, currently treated with destructive laser photocoagulation, represents another potential target for anti-VEGF therapy. The early experience in animal models with proliferative retinopathy and neovascular glaucoma shows that posterior and anterior neovascularizations are very sensitive to anti-VEGF therapy. The outcome of two phase III clinical trials will increase our knowledge of the role of Lucentis® in the treatment of DME.
Keywords: Ranibizumab, Lucentis, Diabetes, Retinopathy, Macular edema
Current Diabetes Reviews
Title: Ranibizumab for Diabetic Retinopathy
Volume: 5 Issue: 1
Author(s): Monica Rodriguez-Fontal, Virgil Alfaro, John B. Kerrison and Eric P. Jablon
Affiliation:
Keywords: Ranibizumab, Lucentis, Diabetes, Retinopathy, Macular edema
Abstract: Ranibizumab (Lucentis®) is a Fab-Antibody with high affinity for VEGF, and is being designed to bind to all VEGF isoforms. This quality makes it a powerful drug for VEGF inhibition. Diseases of retinal and choroidal blood vessels are the most prevalent causes of moderate and severe vision loss in developed countries. Vascular endothelial growth factor plays a critical role in the pathogenesis of many of these diseases. Results of the pilot studies showed that intraocular injections of ranibizumab (Lucentis®) decrease the mean retinal thickness and improve the BCVA in all the subjects. Proliferative diabetic retinopathy, currently treated with destructive laser photocoagulation, represents another potential target for anti-VEGF therapy. The early experience in animal models with proliferative retinopathy and neovascular glaucoma shows that posterior and anterior neovascularizations are very sensitive to anti-VEGF therapy. The outcome of two phase III clinical trials will increase our knowledge of the role of Lucentis® in the treatment of DME.
Export Options
About this article
Cite this article as:
Rodriguez-Fontal Monica, Alfaro Virgil, Kerrison B. John and Jablon P. Eric, Ranibizumab for Diabetic Retinopathy, Current Diabetes Reviews 2009; 5 (1) . https://dx.doi.org/10.2174/157339909787314239
DOI https://dx.doi.org/10.2174/157339909787314239 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Trefoil Factor Family (TFF) Peptides and their Different Roles in the Mucosal Innate Immune Defense and More: An Update
Current Medicinal Chemistry Prematurely Aged Children: Molecular Alterations Leading to Hutchinson-Gilford Progeria and Werner Syndromes
Current Aging Science The Immunomodulatory Effects of Physical Activity
Current Pharmaceutical Design Editorial (Thematic Issue: Nanotechnology for Drug Delivery: Part I)
Current Pharmaceutical Design The Ubiquitin-Proteasome Pathway and Resistance Mechanisms Developed Against the Proteasomal Inhibitors in Cancer Cells
Current Drug Targets Revolutionary Impact of Nanodrug Delivery on Neuroscience
Current Neuropharmacology Targeted Drug Delivery: Trends and Perspectives
Current Drug Delivery Sauropus androgynus Leaves for Health Benefits: Hype and the Science
The Natural Products Journal The Association between Tumor-associated Macrophages and Glioblastoma: A Potential Target for Therapy
Current Pharmaceutical Design Regulation of Eye Development by Protein Serine/Threonine Phosphatases-1 and -2A
Current Molecular Medicine Carbohydrate-Based Recognition Systems in Primary Open Angle Glaucoma
Current Organic Chemistry Analysis of TLC-Bioautography and TLC-Spot Visualization of <i>Atropa accuminata</i> and <i>Atropa belladonna</i> Extracts as Antioxidant and Antibacterial Agents Against Human Pathogenic Bacteria
Current Pharmaceutical Analysis Endothelial Dysfunction and Angiogenesis in Autosomal Dominant Polycystic Kidney Disease
Current Hypertension Reviews Anionic Linear Globular Dendrimer-G2-Ciprofloxacin Nano-Conjugate: Novel Agent against Wilson Disease Cell Model
Letters in Drug Design & Discovery Mass Spectrometry Imaging: Applications in Drug Distribution Studies
Current Drug Metabolism MicroRNAs in CAG Trinucleotide Repeat Expansion Disorders: an Integrated Review of the Literature
CNS & Neurological Disorders - Drug Targets Seeing the Light: Luminescent Reporter Gene Assays
Combinatorial Chemistry & High Throughput Screening Stimuli-responsive Polymeric Nanosystems for Therapeutic Applications
Current Pharmaceutical Design Circadian Clock Gene of Grass Carp (Ctenopharyngodon idellus): Genomic Structure and Tissue Expression Pattern of Period1 Gene
Current Bioinformatics The Traces of Sound: Taking the Road to Skin
Current Rheumatology Reviews